Pharmafile Logo
Pharmafocus logo
Advanced Search

Mylan

Showing 15 posts of 123 posts found.

fda2outsideweb

FDA unanimously recommends Mylan and Biocon’s Herceptin biosimilar

July 14, 2017
Manufacturing and Production, Medical Communications, Sales and Marketing Biocon, Herceptin, Mylan, biosimilar, biotech, drugs, healthcare, life sciences, pharma, pharmaceuticals

Mylan and Biocon have revealed that their biosimilar version of Roche and Genentech’s Herceptin (trastuzumab) has received unanimous recommendation from …

News
gilead-sciences

Gilead to launch injunction against Mylan and Actavis over HIV generics in Ireland

July 6, 2017
Sales and Marketing Actavis, Gilead, HIV, Mylan, Truvada

Gilead is expected to launch injunctive action against rivals Mylan and Actavis over the allegation that they are planning to …

News
heather_bresch_2

Investors demand resignation of Mylan executives over pay packages

June 29, 2017
Sales and Marketing Heather Bresch, Mylan, epipen

As confidence in Mylan continues to fall and share prices plummet after last year’s EpiPen pricing scandal and subsequent PR …

News
fda_sign_web

New rival to EpiPen receives FDA approval to shake up market

June 16, 2017
Medical Communications, Sales and Marketing Adamis, Mylan, Symjepi, epipen

Adamis Pharmaceuticals has revealed that it received FDA approval for its EpiPen rival to enter the market. Its product, to …

News
1280px-epi-pen_1

Mylan overcharged for EpiPen by $1.7 billion, new report says

June 1, 2017
Sales and Marketing Mylan, epipen

More bad news for Mylan as a new report from the Department of Health and Human Services’ Office of the …

News
epi-pen_1_3

Study reveals EpiPens stay effective years after expiration date

May 10, 2017
Research and Development EpiPen expiration, Mylan, Mylan scandal, epipen

The Annals of Internal Medicine has published a study that indicated that EpiPen injectors retain a medically significant proportion of …

News
shutterstock_92671375

Sanofi launches lawsuit against Mylan over “illegal business practices”

April 26, 2017
Research and Development, Sales and Marketing Auvi-Q, Mylan, Sanofi, epipen, lawsuit

In a move that is sure to pile even more pressure onto Mylan after the company’s recent woes, Sanofi has …

News
hero-plus

Mylan hit with fresh lawsuit over EpiPen pricing

April 4, 2017
Manufacturing and Production, Sales and Marketing Mylan, epipen, pricing

Just as it faces worldwide reports that over 80,000 of its EpiPens do not function properly and as the FDA …

News
1280px-epi-pen_1

FDA issues US-wide recall of Mylan’s EpiPen

April 3, 2017
Medical Communications, Sales and Marketing FDA, Mylan, epipen

After recent reports of around 80,000 defective EpiPen’s across Australia, New Zealand, Japan, Norway, Denmark, Finland and Ireland, the FDA …

News

Mylan’s generic of best-selling GSK drug delayed by FDA

March 30, 2017
Sales and Marketing Advair, GSK, Mylan

Mylan’s plan to bring its generic competitor to GSK’s best-selling respiratory drug, Advair, has hit a major snag after it …

News
mylan

Mylan set to close Meda US manufacturing facility

March 28, 2017
Manufacturing and Production Meda, Mylan

Mylan continues to cut away Meda’s US operations to “reduce redundancy” – the latest sees Mylan closing an Illinois-based facility, …

News
mylan

Mylan’s pathway to launch of biosimilar to Herceptin cleared by Roche

March 13, 2017
Manufacturing and Production, Sales and Marketing Genentech, Herceptin, Mylan, Roche, biosimilar

Mylan scored a big victory in its plan to launch its biosimilar to Roche’s blockbuster, Herceptin, after Roche and itself …

News

Pfizer plant receives FDA warning letter for contamination of medicine

March 1, 2017
Manufacturing and Production Copaxone, Mylan, Pfizer, Teva, generics

The FDA has issued a warning letter to Pfizer after inspectors discovered that the plant did not protect properly against …

News
mylan

Mylan pays $96.5 million to settle pay-for-delay case

February 7, 2017
Research and Development, Sales and Marketing Cephalon, Mylan, Teva, antitrust

Mylan has agreed to pay $96.5 million in order to settle an antitrust case. The case was related to the …

News
mylan_plus_hero_720x510_1

Antitrust investigation into Mylan begins over EpiPen

January 31, 2017
Research and Development, Sales and Marketing Mylan, pricing

The Federal Trade Commission has submitted a request to Mylan for information as part of a preliminary investigation into whether …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024